PRGO$14.54
$14.32
Chart
Performance
Key Stats
AI PRGO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyPerrigo Company plc demonstrates solid fundamental strength with a consistent dividend and a diversified product portfolio in the consumer self-care market. While profitability has been mixed and valuation metrics are not exceptionally cheap, its defensive nature and market position support a positive outlook, tempered by some near-term technical considerations.
Thematic
Perrigo operates within the growing consumer self-care market, which benefits from trends in health and wellness, aging populations, and increased consumer focus on preventative health. The company's broad product range and international presence position it well to capture these trends.
Fundamental
Perrigo exhibits a solid financial foundation with a consistent dividend yield and stable revenue, though its profitability has been volatile. The company maintains a significant debt load relative to its market capitalization but covers its interest obligations. Its valuation metrics suggest it is not excessively overvalued but also not a deep value play.
Technical
The stock is trading near its 52-week low but has shown recent positive performance over short-term periods. While trading below its 200-day moving average, there are indications of potential short-term support. Momentum indicators are mixed.
| Factor | Score |
|---|---|
| Consumer Self-Care Market Growth | 85 |
| Demographic Tailwinds | 80 |
| E-commerce Penetration | 75 |
| Regulatory Environment for OTC Products | 65 |
| Brand Diversification and Portfolio Strength | 85 |
| Factor | Score |
|---|---|
| Valuation | 60 |
| Profitability | 40 |
| Growth | 45 |
| Balance Sheet Health | 55 |
| Cash Flow | 70 |
| Dividend | 80 |
| Factor | Score |
|---|---|
| Trend Analysis | 45 |
| Momentum | 65 |
| Support & Resistance | 60 |
| Short-term Performance | 75 |
| Volume | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Attractive Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio of 0.8 (TTM) is low compared to the historical average and industry peers, suggesting potential undervaluation.
Positive Short-Term Performance
The stock has shown positive returns across various short-term periods (5D: 4.34%, 1M: 5.8%, 6M: 12.91%), indicating recent upward momentum.
Bearish Points (7)
Negative Net Income
The company has reported negative net income on a trailing twelve months (TTM) basis (-$71.9M) and in recent annual periods, indicating a lack of overall profitability.
Negative Earnings Per Share (EPS)
The EPS (TTM) is negative (-$1.2), making traditional P/E ratio analysis inappropriate and signaling underlying operational challenges.
Calendar
May 2025
30
Ex-Dividend Date
June 2025
17
Next Dividend Date
August 2025
6
Next Earnings Date
H: $0.62
A: $0.59
L: $0.55
H: 1.09B
A: 1.08B
L: 1.07B
Profile
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Seasonals
Price Target
36.50 USD
The 39 analysts offering 1 year price forecasts for PRGO have a max estimate of 42.00 and a min estimate of 31.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct and pure-play competitor in global consumer healthcare, offering a broad portfolio of OTC medicines and wellness products (e.g., Sensodyne, Advil, Tums), directly overlapping with Perrigo's self-care focus.
Weight: 90
The consumer health spin-off from Johnson & Johnson, Kenvue is a major competitor in various OTC categories (e.g., Tylenol, Motrin, Listerine, Band-Aid), representing a significant market rival to Perrigo's branded and private-label OTC offerings.
Weight: 88
Possesses a substantial Consumer Health division (e.g., Aspirin, Aleve, Claritin, Alka-Seltzer) that directly competes with Perrigo in key OTC therapeutic areas globally.
Weight: 85
Operates a significant Consumer Healthcare business (e.g., Allegra, Dulcolax, Zantac 360, Gold Bond) that competes with Perrigo across various OTC product segments.